<DOC>
	<DOCNO>NCT01813084</DOCNO>
	<brief_summary>RV1729 new medicine develop possible treatment asthma smoke related lung disease ( also know chronic obstructive pulmonary disease - COPD ) . The main purpose study investigate safety , tolerability pharmacokinetics single repeat dos RV1729 .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability Pharmacokinetics Single Repeat Doses RV1729</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Be man woman 18 50 year age , inclusive , time signing informed consent Sign inform consent document indicate understand purpose procedure require study willing participate study If woman childbearing potential , must document menstrual period prior first dose willing able use two form contraception screen 90 day final dose RV1729 , OR If woman nonchildbearing potential must amenorrhoeic great 1 year permanently sterilise , OR If man , must willing able use one contraception method list protocol agree donate sperm , first dose 90 day receive final dose RV1729 . Body mass index 19 30 kg/m2 ( inclusive ) , body weight less 50 kg Vital sign assessment within normal range : blood pressure 90 140 mmHg systolic , inclusive , 40 90 mmHg diastolic ; heart rate 40 100 bpm Have 12lead ECG consistent normal cardiac conduction function Capable comply study restriction procedure include ability use study Dry Powder Inhaler correctly Parts A &amp; B ( healthy volunteer ) Healthy determine physician , base full medical evaluation include medical history , physical examination , laboratory test . Prebronchodilator spirometry reading ( FEV1 FVC ) ≥ 80 % predict value FEV1/FVC ratio &gt; 0.7 screening Are take prescription medication 14 day prior screen agree use prescription medication throughout duration study . Not take counter medication 14 day prior Screening visit final follow visit Part C ( asthma patient ) Documented history asthma , least 6 month prior currently treat need shortacting beta agonist therapy daily inhale corticosteroid Have diagnosis asthma . This may confirm bronchodilator reversibility challenge test . Have prebronchodilator force expiratory volume first second ( FEV1 ) ≥ 65 % predict normal value Treated stable low medium dose inhale corticosteroid least 4 week prior screen Have stable asthma base physician assessment screen asthma exacerbation require augmentation therapy 12 week prior screen hospitalisation asthma 5 year prior screen Not clinical abnormality laboratory parameter outside reference range population study Not take counter ( OTC ) medication herbal medication 14 day prior screen visit final follow visit Upper low respiratory tract infection within 4 week screen visit Clinically significant abnormal value haematology , clinical chemistry urinalysis screen History , reason believe subject history drug alcohol abuse within past 5 year Positive test alcohol drug abuse screen prior dose History clinically significant allergy would contraindicate participation Known allergy study drug excipients formulation Donated blood blood product substantial loss blood ( 500 mL ) within 3 month study Received experimental drug use experimental medical device within 3 month within period le 10 time drug 's half life first dose study drug schedule If woman , positive serum pregnancy test screen admission , pregnant , breastfeed plan become pregnant study Positive test human immunodeficiency virus ( HIV ) 1 2 antibody , hepatitis B virus ( HBV ) infection , hepatitis C antibodies History smoking use nicotinecontaining substance within previous 6 month , positive carbon monoxide test screening Preplanned surgery procedure would interfere conduct study Employee investigator study center , direct involvement propose study study direction investigator study center , well family member employee investigator . Current chronic history liver disease , know hepatic biliary abnormality History regular alcohol consumption within 6 month study The subject unable unwilling comply fully study protocol Subject mentally legally incapacitate Unable unwilling undergo multiple venepuncture procedure subject poor access vein suitable cannulation Any reason Investigator considers make subject unsuitable participate Part C ( asthma patient ) Administration oral , injectable dermal steroid within 3 month intranasal steroid within 1 week screen visit . Has ever episode lifethreatening asthma Any acute chronic illness clinically relevant abnormality asthma Use Cysteine within 24 hour screen throughout study period Has severe asthma base Investigator assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>